Inivata will present data today with collaborators from Gustave Roussy at the 17th World Conference on Lung Cancer in Vienna. The data generated in the joint project explores the clinical benefit for non-small cell lung cancer (NSCLC) patients treated with osimertinib who were EGFR T790M-positive based on a novel, blood-based liquid biopsy test, InVision™.  The researchers looked at response rates specifically in advanced patients with resistance to at least one prior EGFR targeted therapy who were not able to have a tissue biopsy.  They found that of the 48 patients tested, 24 patients (50%) were EGFR T790M-positive.  Of the 24 positive patients, 9 patients had an allele fraction lower than 0.5%, at frequencies that may be missed using less sensitive assays.  For the patients who were treated with osimertinib and evaluable for treatment response, the objective response rate was 62.5% with the remaining patients having stable disease as their best overall response. The study supports the use of liquid biopsies as a surrogate marker for T790M in tumor tissue, avoiding the need for invasive tumor biopsies for personalizing treatment in lung cancer patients.

We are impressed with the performance of our InVision platform across a variety of clinical scenarios in terms of robustness, reproducibility, and actionability.

Clive Morris
Chief Medical Officer, Inivata

On December 7, Inivata will present analytical performance data for InVision comparing results from both their Cambridge, UK laboratory as well as their U.S. CLIA certified laboratory.  The data showed high concordance across both laboratories including strong correlation of InVision ctDNA results compared to a digital PCR-based approach.

“We are impressed with the performance of our InVision platform across a variety of clinical scenarios in terms of robustness, reproducibility, and actionability.  The results are encouraging as we continue to generate further data to support clinical use of our InVision platform,” said Clive Morris, Chief Medical Officer of Inivata.

Read more here.